TelomEYE Pharmaceuticals Raises $1M in Post-Seed Funding at a $10M valuation to Develop New Generation of Eye Disease Therapies.
TelomEYE Pharmaceuticals Raises $1M in Post-Seed Funding at a $10M valuation to Develop New Generation of Eye Disease Therapies.
TelomEYE Pharmaceutical Corporation, working on a new generation of ophthalmologic therapies, raises $1 million USD post-seed funding round, valuing the company at $10 million USD.
The round was co-led by healthcare mogul Mehmet Ali Aydınlar, Re-Pie Venture Capital Fund, and investment banker Kerim Kotan, along with other angel investors. With this financing, TelomEYE will be able to complete phase I & II human studies for their novel, patented therapy in ophthalmology. This therapy could be the start of a new era for treating many ophthalmologic age-related disorders, including presbyopia, cataracts and even macular degeneration.
TelomEYE is a privately held Canadian ophthalmology & biotech company founded in September 2021 by ophthalmologists Iskender Alkin Solmaz MD, Isilay Kavadarli MD and entrepreneur Kubilay Turkmen in Ontario, Canada. The founders had self-funded TelomEYE initially for novel formulation development, patent applications and pre-human animal trials.
SZA is wholly owned and controlled by Mr. Mehmet Ali Aydınlar, the founder, minority shareholder and Chairman of Acibadem Group. The Group is one of the largest health groups in the region, with $3 billion turnover and 21 hospitals, 13 medical centers in Europe and CIS.
Re-Pie Portfolio Management Inc. is one of the largest investment funds in Turkey, managing nearly $2 billion under 35 separate funds (private equity, venture capital and real estate).
